Novartis AG has gained FDA approval to market Kisqali (ribociclib), in combination with an aromatase inhibitor, as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor positive (HR+), HER2-negative advanced or metastatic breast cancer.